Inhibrx Biosciences, Inc. (INBX) stock
INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$74.33+5.27 (+7.63%)
Close on Nov 19, 2026Market cap $1.09BP/E –Yield –
Inhibrx Biosciences free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Inhibrx Biosciences's free cash flow for the twelve months ending Sep 30, 2026 was -$132.70M. For fiscal 2025 it was -$129.83M. The highest annual figure on record is -$33.89M in fiscal 2019.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$129.83M | – |
| FY2024 | Dec 31, 2024 | -$197.01M | – |
| FY2023 | Dec 31, 2023 | -$197.90M | – |
| FY2022 | Dec 31, 2022 | -$115.99M | – |
| FY2021 | Dec 31, 2021 | -$81.19M | – |
| FY2020 | Dec 31, 2020 | -$49.33M | – |
| FY2019 | Dec 31, 2019 | -$33.89M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$34.63M | – |
| Q2 FY2026 | Jun 30, 2026 | -$29.92M | – |
| Q1 FY2026 | Mar 31, 2026 | -$38.03M | – |
| Q4 FY2025 | Dec 31, 2025 | -$30.12M | – |
| Q3 FY2025 | Sep 30, 2025 | -$33.83M | – |
| Q2 FY2025 | Jun 30, 2025 | -$29.95M | – |
| Q1 FY2025 | Mar 31, 2025 | -$35.92M | – |
| Q4 FY2024 | Dec 31, 2024 | -$43.74M | – |
| Q3 FY2024 | Sep 30, 2024 | -$30.53M | – |
| Q2 FY2024 | Jun 30, 2024 | -$58.57M | – |
| Q1 FY2024 | Mar 31, 2024 | -$64.17M | – |
| Q4 FY2023 | Dec 31, 2023 | -$60.26M | – |
| Q3 FY2023 | Sep 30, 2023 | -$55.06M | – |
| Q2 FY2023 | Jun 30, 2023 | -$42.62M | – |
| Q1 FY2023 | Mar 31, 2023 | -$39.97M | – |
| Q4 FY2022 | Dec 31, 2022 | -$30.87M | – |
| Q3 FY2022 | Sep 30, 2022 | -$30.82M | – |
| Q2 FY2022 | Jun 30, 2022 | -$27.24M | – |
| Q1 FY2022 | Mar 31, 2022 | -$27.06M | – |
| Q4 FY2021 | Dec 31, 2021 | -$22.89M | – |
| Q3 FY2021 | Sep 30, 2021 | -$13.84M | – |
| Q2 FY2021 | Jun 30, 2021 | -$22.79M | – |
| Q1 FY2021 | Mar 31, 2021 | -$21.66M | – |
| Q4 FY2020 | Dec 31, 2020 | -$16.00M | – |
| Q3 FY2020 | Sep 30, 2020 | -$14.18M | – |
| Q2 FY2020 | Jun 30, 2020 | -$11.67M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.48M | – |
| Q4 FY2019 | Dec 31, 2019 | -$12.28M | – |
See a number that looks wrong?